Clinical Trial Protocol
Iranian Registry of Clinical Trials

18 Sep 2026

Fasted-state in vivo bioequivalence study of Celecoxib 100 mg tablet manufactured by Farnoush Daru Teb Co. compared with innovator product

Protocol summary

Study aim
Investigating bioequivalence of Celecoxib tablet compared to innovator product

Design
This randomized clinical trial with a control group will be conducted in a cross-over, open-label; on 24 healthy volunteers. A lottery method will be used for randomization.

Settings and conduct
After administration of one 100mg tablet to volunteer, the blood samples will be collected in predetermined time intervals up to 48 hours. The samples will be stored in freezer -4 degrees centigrade until analysis and sample quantitation. the study will be performed in Faculty of Pharmacy, Tabriz University of Medical Sciences. This trial will be conducted in an open-label fashion.

Participants/Inclusion and exclusion criteria
Inclusion criteria: General Health (in terms of Liver, Heart, and Kidney); Age (18-60 years old). Exclusion criteria: Smoking; history of cardiovascular; liver and kidney disease; pregnancy; alcohol and drug addiction; history of drug allergy.

Intervention groups
Intervention group will receive one test drug product. Blood samples will be taken from the volunteers for 48 hours at the mentioned time points after drug administration and the concentration of drug in blood samples will be measured by liquid chromatography equipped with mass spectroscopy detector. Control group will receive one reference drug product. Blood samples will be taken from the volunteers for 48 hours at the mentioned time points after drug administration and the concentration of drug in blood samples will be measured by liquid chromatography equipped with mass spectroscopy detector.

Main outcome variables
Drug plasma concentration

General information

Reason for update

Acronym

IRCT registration information
IRCT registration number: **IRCT20210519051345N15**
Registration date: **2022-08-17, 1401/05/26**
Registration timing: **prospective**

Last update: **2022-08-17, 1401/05/26**
Update count: **0**

Registration date
2022-08-17, 1401/05/26

Registrant information

Name
Parvin Zakeri-Milani

Name of organization / entity

Country
Iran (Islamic Republic of)

Phone
+98 41 3334 8801

Email address
pzakeri@tbzmed.ac.ir

Recruitment status
Recruitment complete

Funding source

Expected recruitment start date
2022-09-16, 1401/06/25

Expected recruitment end date
2023-03-16, 1401/12/25

Actual recruitment start date
empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Fasted-state in vivo bioequivalence study of Celecoxib 100 mg tablet manufactured by Farnoush Daru Teb Co. compared with innovator product

Public title
Investigating the in vivo bioequivalence of Celecoxib 100 mg tablet
Purpose
Other
Inclusion/Exclusion criteria
Inclusion criteria:
General Health (in terms of Liver, Heart and Kidney)
Exclusion criteria:
Smoking, History of cardiovascular disease, liver and kidney disease, Pregnancy, Alcohol and drug addiction, History of drug allergy
Age
From **18 years** old to **59 years** old
Gender
Both

Phase
Bioequivalence
Groups that have been masked
No information
Sample size
Target sample size: **24**
Randomization (investigator's opinion)
Randomized
Randomization description
To randomly assign participants in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope. Numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of both groups will change for the second period.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Biomedical Research Committe, Tabriz University of Medical Sciences
Street address
No.2 Central Building 3rd Floor, University of Medical Sciences, Daneshgah st.
City
Tabriz
Province
East Azarbaijan
Postal code
51664-14766
Approval date
2022-08-01, 1401/05/10
Ethics committee reference number
IR.TBZMED.REC.1401.402

Health conditions studied

1

Description of health condition studied
In the present study, the products will be administered to healthy volunteers.
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Plasma concentration of drug
Timepoint
0.5-48 hours in predetermined time intervals after drug administration (0.5, 1,1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 24, 48 h)
Method of measurement
HPLC (High performance liquid chromatography)

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: Intervention group will receive a single test drug product. Blood samples will be collected for48 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be measured by liquid chromatography equipped with mass spectroscopy detector
Category
Treatment - Drugs

2

Description
Control group: Control group will receive a single reference drug product. Blood samples will be collected for 48 hours at the mentioned times after drug administration and the concentration of drug in blood

samples will be measured by liquid chromatography equipped with mass spectroscopy detector.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Tabriz University of Medical Sciences, Faculty of Pharmacy

Full name of responsible person

Parvin Zakeri-Milani

Street address

Faculty of Pharmacy, University of Medical Sciences, Golgasht st., Attar Neishaboori st.

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Parviz Shahabi

Street address

No.2 Central Building 3rd Floor, Daneshgah st. Tabriz University of Medical Science

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

shahabip@tbzmed.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

No

Title of funding source

Farnoosh Darou Teb Pharmaceutical Company

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Industry

Person responsible for general inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, University of Medical Sciences, Golgasht st., Attar Neishaboori st.

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Tabriz University of Medical Sciences

Full name of responsible person

Parvin Zakeri-Milani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Medical Pharmacy

Street address

Faculty of Pharmacy, University of Medical Sciences, Golgasht st., Attar Neishaboori st.

City

Tabriz

Province

East Azarbaijan

Postal code

51664-14766

Phone

+98 41 3334 8801

Email

pzakeri@tbzmed.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Tabriz University of Medical Sciences

Full name of responsible person
Parvin Zakeri-Milani

Position
Professor

Latest degree
Ph.D.

Other areas of specialty/work
Medical Pharmacy

Street address
Faculty of Pharmacy, University of Medical Sciences, Golgasht st., Attar Neishaboori st.

City
Tabriz

Province
East Azarbaijan

Postal code
51664-14766

Phone
+98 41 3334 8801

Email
pzakeri@tbzmed.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available

Study Protocol
Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available

Analytic Code
Not applicable

Data Dictionary
Not applicable